New drug DM002 enters first human tests for Hard-to-Treat cancers
NCT ID NCT06751329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; second, giving that best dose to more participants to check safety and see if tumors shrink. Participants will have frequent visits and be followed for about 30 days after treatment ends.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care Wollongong
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scientia Clinical Research
RECRUITINGRandwick, New South Wales, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas, MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73190, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••